Company also commits to investing up to
$100 million in German early-stage
life sciences ecosystem
INDIANAPOLIS, Nov. 17,
2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:
LLY) today announced plans to construct a new $2.5 billion high-tech manufacturing site in
Alzey, Rhineland-Palatinate, Germany. This new facility will further expand
the company's global parenteral (injectable) product and device
manufacturing network and support an increased demand for Lilly's
medicines, including its diabetes and obesity portfolio. The
company has launched 21 treatments since 2014 and plans to launch
several more in the coming years.
"Every investment into our manufacturing capacity around the
world is a renewed commitment to patients today – and to those who
may need our medicines tomorrow," said Edgardo Hernandez,
executive vice president and president, Lilly manufacturing
operations. "This state-of-the-art parenteral site with the latest
technology will enable us to continue to deliver medicines with
safety first and quality always around the world."
With the planned manufacturing facility in Alzey, Lilly will
operate a total of six manufacturing sites in Europe, including one in nearby Fegersheim,
France. Lilly's ongoing
investments in Europe will create
operational synergies, strengthen university and government
relationships, support the early-stage life science ecosystem, and
diversify the growing Lilly presence in Europe.
With extensive experience across the pharmaceutical industry,
Germany's workforce will play a
vital role in bolstering Lilly's incretin supply when the new site
is operational beginning in 2027. The site in Alzey will
employ up to 1,000 highly skilled workers such as engineers,
operators and scientists, who will leverage state-of-the-art
technology, including automation and high-speed manufacturing
lines, to produce life-changing medicines. In addition, an
estimated 1,900 jobs will be created during construction, which is
scheduled to begin in 2024. Lilly's investment in Alzey is
contingent upon finalization of government permitting and local
approvals.
"The decision to locate here is good news for Germany as a business location," said Dr.
Robert Habeck, vice chancellor and
federal minister for Economic Affairs and Climate Action. "It
creates new and future-oriented jobs, shows the confidence of
companies in the attractiveness of Germany as a pharmaceutical and industrial
location and helps to improve healthcare for our citizens. The new
location will make an important contribution to industrial value
creation in Germany with high-tech
production facilities and research and development."
Lilly has announced investments of more than $11 billion in its global manufacturing footprint
in the past three years to help ensure the safe and reliable supply
of Lilly's innovative medicines. The company continues to
invest in the expansion of its global manufacturing to address the
growth expected from potential new medicines to treat diabetes and
obesity, Alzheimer's disease, cancer and autoimmune conditions.
"As we look to usher in the next generation of medicines, we're
looking for people and partners who share our passion for improving
health outcomes," said Ilya Yuffa,
executive vice president and president, Lilly International. "With
this new investment, we hope to spark a new era of collaboration
and innovation in Germany and the
European Union defined by our shared purpose to find lasting
solutions for patients."
The company is also announcing an investment of up to
$100 million to dramatically increase
its footprint in Germany's
early-stage biotech ecosystem. These investments will focus on
biotech and the life sciences venture capital funds – expanding
Lilly's incubator and accelerator engagements, and strengthening
Lilly's ties and activities with world-renowned academic and
innovation partners. With these investments, Lilly will pursue
strategic partnerships and collaborations utilizing a variety of
models that meet a range of business needs, including capital and
equity investments; world-class lab space; and outstanding research
and development capabilities and expertise to help accelerate
innovative medicines that meet the needs of people globally.
"This investment strengthens the Federal Government in its
efforts to make Germany more
attractive again as a pharmaceutical location," added Prof. Dr.
Karl Lauterbach, federal minister of
health. "It shows good innovative products can be reliably
developed and produced in Germany.
But we will continue to improve the framework conditions for
research and production. This will ensure that patients have rapid
access to new treatment options and make us more independent from
fragile supply chains. Europe
needs a strong pharmaceutical industry and research – not least for
good and secure healthcare. Germany wants to provide new stimuli
here."
About Lilly
Lilly unites caring with discovery to
create medicines that make life better for people around the world.
We've been pioneering life-changing discoveries for nearly 150
years, and today our medicines help more than 51 million
people across the globe. Harnessing the power of biotechnology,
chemistry and genetic medicine, our scientists are urgently
advancing new discoveries to solve some of the world's most
significant health challenges, redefining diabetes care, treating
obesity and curtailing its most devastating long-term effects,
advancing the fight against Alzheimer's disease, providing
solutions to some of the most debilitating immune system disorders,
and transforming the most difficult-to-treat cancers into
manageable diseases. With each step toward a healthier world, we're
motivated by one thing: making life better for millions more
people. That includes delivering innovative clinical trials that
reflect the diversity of our world and working to ensure our
medicines are accessible and affordable. To learn more,
visit Lilly.com and Lilly.com/news or follow us
on Facebook, Instagram and LinkedIn. C-LLY
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about planned capital investments in new manufacturing sites
and related initiatives and reflects Lilly's current beliefs and
expectations. However, there can be no assurance that Lilly will
successfully or timely complete the planned manufacturing sites or
that Lilly will otherwise execute its strategy as planned. There
are substantial risks and uncertainties in facilities construction,
the manufacturing process and development, and commercialization of
pharmaceutical products which could impact the launch of potential
new products or the supply and overall commercial success of our
products. For further discussion of these and other risks and
uncertainties, see Lilly's most recent Form 10-K and Form 10-Q
filings with the United States Securities and Exchange Commission.
Except as required by law, Lilly undertakes no duty to update
forward-looking statements to reflect events after the date of this
release.
Refer
to:
|
Molly McCully;
mccully_molly@lilly.com; (317) 478-5423 (Media)
|
|
Stefanie Prodouz;
stefanie.prodouz@lilly.com; (317) 287-9899 (Media)
|
|
Joe Fletcher;
jfletcher@lilly.com; 317-296-2884 (Investors)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-to-expand-injectable-manufacturing-capacity-with-planned-2-5-billion-site-in-germany-301990884.html
SOURCE Eli Lilly and Company